Terms ending in 2030
Every in-force patent on Adimab, LLC's record whose computed term ends in 2030, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 10,189,894 | Rationally Designed, Synthetic Antibody Libraries and Uses Therefor In force · High confidence | Adimab, LLC | In force | High confidence | |
| US 8,877,688 | Rationally Designed, Synthetic Antibody Libraries and Uses Therefor In force · Medium confidence | Adimab, LLC | In force | Medium confidence |
2 of 2 patents shown. Soonest term end first, then patent number.
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.